|
1
|
Kernochan LE and Garcia RL:
Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus:
Advances in elucidation of biologic and clinical characteristics. J
Natl Compr Canc Netw. 7:550–557. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lopez-Garcia MA and Palacios J: Pathologic
and molecular features of uterine carcinosarcomas. Semin Diagn
Pathol. 27:274–286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh R: Review literature on uterine
carcinosarcoma. J Cancer Res Ther. 10:461–468. 2014.PubMed/NCBI
|
|
4
|
Liao CI, Caesar MA, Lee D, Chan A, Darcy
KM, Tian C, Kapp DS and Chan JK: Increasing incidence of uterine
carcinosarcoma: A United States cancer statistics study. Gynecol
Oncol Rep. 40:1009362022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Concin N, Matias-Guiu X, Vergote I, Cibula
D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti
A, et al: ESGO/ESTRO/ESP guidelines for the management of patients
with endometrial carcinoma. Int J Gynecol Cancer. 31:12–39. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kounelis S, Jones MW, Papadaki H, Bakker
A, Swalsky P and Finkelstein SD: Carcinosarcomas (malignant mixed
mullerian tumors) of the female genital tract: Comparative
molecular analysis of epithelial and mesenchymal components. Hum
Pathol. 29:82–87. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McCluggage WG: Malignant biphasic uterine
tumours: Carcinosarcomas or metaplastic carcinomas? J Clin Pathol.
55:321–325. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanthan R and Senger JL: Uterine
carcinosarcomas (malignant mixed Müllerian tumours): A review with
special emphasis on the controversies in management. Obstet Gynecol
Int. 2011:4707952011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsuzaki S, Klar M, Matsuzaki S, Roman
LD, Sood AK and Matsuo K: Uterine carcinosarcoma: Contemporary
clinical summary, molecular updates, and future research
opportunity. Gynecol Oncol. 160:586–601. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kadota K, Haba R, Ishikawa M, Kushida Y,
Katsuki N, Hayashi T, Miyai Y, Bando K, Shiota A and Hata T:
Uterine cervical carcinosarcoma with heterologous mesenchymal
component: A case report and review of the literature. Arch Gynecol
Obstet. 280:839–843. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wada H, Enomoto T, Fujita M, Yoshino K,
Nakashima R, Kurachi H, Haba T, Wakasa K, Shroyer KR, Tsujimoto M,
et al: Molecular evidence that most but not all carcinosarcomas of
the uterus are combination tumors. Cancer Res. 57:5379–5385.
1997.PubMed/NCBI
|
|
12
|
Liu Y, Weber Z, San Lucas FA, Deshpande A,
Jakubek YA, Sulaiman R, Fagerness M, Flier N, Sulaiman J, Davis CM,
et al: Assessing inter-component heterogeneity of biphasic uterine
carcinosarcomas. Gynecol Oncol. 151:243–249. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jonson AL, Bliss RL, Trusnikovsky A,
Judson P, Argenta P, Carson L, Dusenbery K and Downs LS Jr:
Clinical features and outcomes of uterine and ovarian
carcinosarcoma. Gynecol Oncol. 100:561–564. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rauh-Hain JA, Shoni M, Schorge JO, Goodman
A, Horowitz NS and del Carmen MG: Prognostic determinants in
patients with uterine and ovarian carcinosarcoma. J Reprod Med.
58:297–304. 2013.PubMed/NCBI
|
|
15
|
Adachi Y, Nonogaki H, Minamiguchu S, Li M
and Ikehara S: Carcinosarcoma of the uterus: A case report. Mol
Clin Oncol. 4:571–573. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Callister M, Ramondetta LM, Jhingran A,
Burke TW and Eifel PJ: Malignant mixed Müllerian tumors of the
uterus: Analysis of patterns of failure, prognostic factors, and
treatment outcome. Int J Radiat Oncol Biol Phys. 58:786–796. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Villena-Heinsen C, Diesing D, Griesinger
G, Maas N, Diedrich K and Friedrich M: Carcinosarcomas-a
retrospective analysis of 21 patients. Anticancer Res.
26:4817–4823. 2006.PubMed/NCBI
|
|
18
|
Chen X, Arend R, Hamele-Bena D, Tergas AI,
Hawver M, Tong GX, Wright TC and Wright JD: Uterine
carcinosarcomas: Clinical, histopathologic and immunohistochemical
characteristics. Int J Gynecol Pathol. 36:412–419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Swisher EM, Gown AM, Skelly M, Ek M,
Tamimi HK, Cain JM, Greer BE, Muntz HG and Goff BA: The expression
of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67
antigen in uterine malignant mixed mesodermal tumors and
adenosarcoma. Gynecol Oncol. 60:81–88. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nicotina PA, Ferlazzo G and Vincelli AM:
Proliferation indices and p53-immunocytochemistry in uterine mixed
mullerian tumors. Histol Histopathol. 12:967–972. 1997.PubMed/NCBI
|
|
21
|
Yoshida Y, Kurokawa T, Fukuno N,
Nishiokawa Y, Kamitani N and Kotsuji F: Markers of apoptosis and
angiogenesis indicate that carcinomatous components play an
important role in the malignant behavior of uterine carcinosarcoma.
Hum Pathol. 31:1448–1454. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikeda K, Tate G, Suzuki T and Mitsuya T:
Effusion cytodiagnosis of carcinosarcoma derived from the female
genital tract: Immunohistochemical features of MMP-7 and Ki-67 and
immunofluorescence double staining analyses of eight cases. Gynecol
Oncol. 97:323–329. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee SJ, Kim HS, Kim HS, Chun YK, Hong YR
and Lee JH: Immunohistochemical study of DNA topoisomerase I, p53,
and Ki-67 in uterine carcinosarcomas. Hum Pathol. 38:1226–1231.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kanthan R, Senger JL and Diudea D:
Malignant mixed mullerian tumors of the uterus: Histopathological
evaluation of cell cycle and apoptotic regulatory proteins. World J
Surg Oncol. 8:602010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koivisto-Korander R, Butzow R, Koivistro
AM and Leminen A: Immunohistochemical studies on uterine
carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma:
Expression and prognostic importance of ten different markers.
Tumor Biol. 32:451–459. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bałon B, Kaznowska E, Ignatov A, Steć A,
Semczuk-Sikora A, Schneider-Stock R, Jóźwik M, Sulkowski S,
Cybulski M, Szumiło J and Semczuk A: p53 is not related to Ki-67
immunostaining in the epithelial and mesenchymal components of
female genital tract carcinosarcomas. Oncol Rep. 30:1661–1668.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yue X, Utsunomita H, Akahira JI, Suzuki F,
Ito K, Nagase S, Sasano H and Yaegashi N: Expression of steroid and
xenobiotic receptor in uterine carcinosarcoma, leiomyosarcoma and
endometrial stromal sarcoma. Oncol Lett. 5:835–839. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou Y, Huang H, Yuan LJ, Xiong Y, Huang
X, Lin JX and Zheng M: CD146 as an adverse prognostic factor in
uterine sarcoma. Eur J Med Res. 20:672015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tochimoto M, Oguri Y, Hashimura M, Konno
R, Matsumoto T, Yokoi A, Kodera Y and Saegusa M: S100A4/non-muscle
myosin II signaling regulates epithelial-mesenchymal transition and
stemness in uterine carcinosarcoma. Lab Invest. 100:682–695. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Female Genital Tumors, . WHO
classification of tumors. 5th edition. Vol. 4. WHO Classification
of Tumours Editorial Board; 2020
|
|
31
|
Koksas M, Amant F, Mirza MR and Creutzberg
CL: Cancer of the corpus uteri: 2021 update. Int J Gynecol Obstet.
155 (Suppl 1):S45–S60. 2021. View Article : Google Scholar
|
|
32
|
Hassab El-Naby NED, Muhammad EMS,
El-Nashar AT, Sotouhy SMM and Mahmoude SM: P0173 use of PTEN, PCNA,
and β-cathenin to differentiate between endometrial hyperplasia and
endometrial adenocarcinoma. Eur J Cancer. 50 (Suppl 4):E592014.
View Article : Google Scholar
|
|
33
|
Lameira AG, Pontes FS, Guimarães DM, Alves
AC, de Jesus AS, Pontes HA and Pinto Ddos S Jr: MCM3 could be a
better marker than Ki-67 for evaluation of dysplastic oral lesions:
An immunohistochemical study. J Oral Pathol Med. 43:427–434. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kreisholt JM, Sorensen M, Jensen PB,
Nielsen BS, Andersen CB and Sehested M: Immunohistochemical
detection of DNA topoisomerase IIalpha, P-glycoprotein and
multidrug resistance protein (MRP) in small-cell and non-small-cell
lung cancer. Br J Cancer. 77:1469–1473. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mittal K, Soslow R and McCluggage WG:
Application of immunohistochemistry to gynecologic pathology. Arch
Pathol Lab Med. 132:402–423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kaspar HG and Crum CP: The utility of
immunohistochemistry in the differential diagnosis of gynecologic
disorders. Arch Pathol Lab Med. 139:39–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hirsch MS and Watkins J: A comprehensive
review of biomarker use in the gynecologic tract including
differential diagnoses and diagnostic pitfalls. Adv Anat Pathol.
27:164–192. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McCluggage WG: Immunohistochemical and
functional biomarkers of value in female genital tract lesions. Int
J Gynecol Pathol. 25:101–120. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Semczuk A, Skomra D, Chyzynska M, Szewczuk
W, Olcha P and Korobowicz E: Immunohistochemical analysis of
carcinomatous and sarcomatous components in the uterine
carcinosarcoma: A case report. Pathol Res Pract. 204:203–207. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Semczuk A, Zakrzewski PK, Forma E,
Cygankiewicz AI, Semczuk-Sikora A, Bryś M, Rechberger T and
Krajewska WM: TGFβ-pathway is down-regulated in a uterine
carcinosarcoma: A case study. Pathol Res Pract. 209:740–744. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Semczuk A, Colas E, Walczyna B, Joźwik M,
Pyra A, Semczuk-Sikora A and Rechberger T: Coexistence of
homologous-type cervical carcinosarcoma with endometrioid-type G1
endometrial cancer: A case report with an immunohistochemical
study. Int J Clin Exp Pathol. 7:7191–7195. 2014.PubMed/NCBI
|
|
42
|
Semczuk A, Ignatov A, Obrzut B, Reventos J
and Rechberger T: Role of p53 pathway alterations in uterine
carcinosarcomas (malignant mixed Müllerian tumors). Oncology.
87:193–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Semczuk A, Lewkowicz D, Jóźwik M, Mrozek
A, Gogacz M, Semczuk-Sikora A and Rechberger T: Bilateral lymph
node metastases from primary uterine carcinosarcoma: An
immunohistochemical case study. Int J Clin Exp Pathol. 9:8754–8758.
2016.
|
|
44
|
Watanabe M, Shimizu K, Kato H, Imai H,
Nakano H, Sugawa M and Shiraishi T: Carcinosarcoma of the uterus:
Immunohistochemical and genetic analysis of clonality of one case.
Gynecol Oncol. 82:563–567. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
de Jong RA, Nijman HW, Wijbrandi TF,
Reyners AK, Boezen HM and Hollema H: Molecular markers and clinical
behavior of uterine carcinosarcomas: Focus on the epithelial tumor
component. Mod Pathol. 24:1368–1379. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Iwasa Y, Haga H, Konishi I, Kobashi Y,
Higuchi K, Katsuyama E, Minamiguchi S and Yamabe H: Prognostic
factors in uterine carcinosarcoma: A clinicopathologic study of 25
patients. Cancer. 82:512–519. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sreenan JJ and Hart WR: Carcinosarcomas of
the female genital tract. A pathologic study of 29 metastatic
tumors: Further evidence for the dominant role of the epithelial
component and the conversion theory of histogenesis. Am J Surg
Pathol. 19:666–674. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bologna-Molina R, Beyoda-Borella AM,
Soria-Moreira L and Soría-Suárez S: Molecular biomarkers of cell
proliferation in amenoblastomas. World J Stomatol. 2:79–85. 2013.
View Article : Google Scholar
|
